OBJECTIVE: Compared with standard, @entity15531 ( @entity15531 ) therapies for @entity263 , focal approaches may provide equivalent oncologic outcomes with fewer adverse effects. The purpose of this study was to compare organ-at-risk (OAR) dosimetry between hemigland (HG) and @entity15531 stereotactic body radiotherapy (SBRT) plans. METHODS: Volumetric-modulated arc radiotherapy-based SBRT plans were designed to treat the left HG, right HG and @entity15531 in eight @entity1 , using five fractions of 8   Gy. OARs of interest included the contralateral HG, rectum, urinary bladder, urethra, penile bulb and contralateral neurovascular bundle. RESULTS: Rectal V80% (the percentage of a normal structure receiving a dose of 80%) and V90% were significantly lower with HG plans than with @entity15531 plans (median values of 4.4 vs 2.5   cm(3) and 2.1 vs 1.1   cm(3), respectively, p   <   0.05 by Student's t-test). Bladder V50% was also reduced significantly in HG plans (32.3 vs 17.4   cm(3), p   <   0.05), with a trend towards reduction of V100% (3.4 vs 1.3   cm(3), p   =   0.09). Urethral maximum dose and mean doses to the penile bulb and contralateral neurovascular bundle were also reduced significantly (42.0 vs 39.7   Gy, p   <   0.00001; 13.3 vs 9.2   Gy, p   <   0.05; and 40.2 vs 19.3   Gy, p   <   0.00001, respectively). CONCLUSION: Targeting an HG volume rather than a @entity15531 volume when delivering SBRT can offer statistically significant reductions for all OARs. Given the large magnitude of the reduction in dose to these OARs, it is anticipated that HG SBRT could offer a superior @entity137 profile when compared with @entity15531 SBRT. This is likely to be most relevant in the context of salvaging a local failure after radiation therapy. Advances in knowledge: The dosimetric feasibility of HG SBRT is demonstrated. When compared with @entity15531 SBRT plans, the HG plans demonstrate statistically significant and large magnitude reduction in doses to the rectum, bladder, urethra, penile bulb and contralateral neurovascular bundle, suggesting the possibility of improved @entity137 outcomes with HG SBRT. This is likely to be most relevant in the context of salvaging a local failure after radiation therapy.

Dosimetric benefits of hemigland stereotactic body radiotherapy for XXXX : implications for focal therapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity15531 :: ('MESH:C531766', 'Disease') :: ['WG', 'whole-gland']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
